OLEMA PHARMACEUTICALS, INC. Increase Decrease In Operating Lease Liability
OLEMA PHARMACEUTICALS, INC. (OLMA) reported Increase Decrease In Operating Lease Liability of -$627.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-10
- OLEMA PHARMACEUTICALS, INC. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$314.00K.
- OLEMA PHARMACEUTICALS, INC. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$313.00K.
- OLEMA PHARMACEUTICALS, INC. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$313.00K.
- OLEMA PHARMACEUTICALS, INC. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$311.00K.
- OLEMA PHARMACEUTICALS, INC. increase decrease in operating lease liability for fiscal 2025 was -$1.24M.
- OLEMA PHARMACEUTICALS, INC. increase decrease in operating lease liability for fiscal 2024 was -$1.16M.
- OLEMA PHARMACEUTICALS, INC. increase decrease in operating lease liability for fiscal 2023 was -$1.23M.
- OLEMA PHARMACEUTICALS, INC. increase decrease in operating lease liability for fiscal 2022 was -$1.27M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$314.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$627.00K 10-Q · filed 2026-08-10 | -$940.00K derived: sum of 3 quarters · filed 2026-08-10 | -$1.25M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$313.00K 10-Q · filed 2026-05-12 | -$626.00K derived: sum of 2 quarters · filed 2026-05-12 | -$937.00K derived: sum of 3 quarters · filed 2026-05-12 | -$1.25M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$313.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$624.00K derived: sum of 2 quarters · filed 2026-03-16 | -$935.00K derived: sum of 3 quarters · filed 2026-08-10 | -$1.24M 10-K · filed 2026-03-16 |
| 2025-09-30 | -$311.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$622.00K derived: sum of 2 quarters · filed 2026-08-10 | -$931.00K 10-Q · filed 2025-11-10 | -$1.24M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$311.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$620.00K 10-Q · filed 2026-08-10 | -$925.00K derived: sum of 3 quarters · filed 2026-08-10 | -$1.23M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$309.00K 10-Q · filed 2026-05-12 | -$614.00K derived: sum of 2 quarters · filed 2026-05-12 | -$918.00K derived: sum of 3 quarters · filed 2026-05-12 | -$1.21M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$305.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$609.00K derived: sum of 2 quarters · filed 2026-03-16 | -$902.00K derived: sum of 3 quarters · filed 2026-03-16 | -$1.16M 10-K · filed 2026-03-16 |
| 2024-09-30 | -$304.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$597.00K derived: sum of 2 quarters · filed 2025-11-10 | -$857.00K 10-Q · filed 2025-11-10 | -$1.12M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$293.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$553.00K 10-Q · filed 2025-08-11 | -$816.00K derived: sum of 3 quarters · filed 2025-08-11 | -$1.13M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | -$260.00K 10-Q · filed 2025-05-13 | -$523.00K derived: sum of 2 quarters · filed 2025-05-13 | -$838.00K derived: sum of 3 quarters · filed 2025-05-13 | -$1.17M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$263.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | -$578.00K derived: sum of 2 quarters · filed 2025-03-18 | -$905.00K derived: sum of 3 quarters · filed 2025-03-18 | -$1.23M 10-K · filed 2025-03-18 |
| 2023-09-30 | -$315.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$642.00K derived: sum of 2 quarters · filed 2024-11-12 | -$968.00K 10-Q · filed 2024-11-12 | -$1.29M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$327.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$653.00K 10-Q · filed 2024-08-06 | -$975.00K derived: sum of 3 quarters · filed 2024-08-06 | -$1.29M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$326.00K 10-Q · filed 2024-05-08 | -$648.00K derived: sum of 2 quarters · filed 2024-05-08 | -$968.00K derived: sum of 3 quarters · filed 2024-05-08 | -$1.28M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$322.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | -$642.00K derived: sum of 2 quarters · filed 2024-03-11 | -$959.00K derived: sum of 3 quarters · filed 2024-03-11 | -$1.27M 10-K · filed 2024-03-11 |
| 2022-09-30 | -$320.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$637.00K derived: sum of 2 quarters · filed 2023-11-07 | -$952.00K 10-Q · filed 2023-11-07 | |
| 2022-06-30 | -$317.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$632.00K 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | -$315.00K 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | -$988.00K 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |